Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jingzhui Tongluo Capsule is a Traditional Chinese Medicine (TCM) formulation developed by Zhuhai Xingguang Pharmaceutical for the treatment of cervical spondylotic radiculopathy (CSR). It is specifically indicated for patients presenting with the "Cold and Blood Stasis Blocking Collaterals" syndrome (寒瘀阻络证), a TCM diagnostic category characterized by symptoms such as neck pain, numbness in the upper extremities, and restricted movement. The capsule is designed to warm the meridians, disperse cold, and promote blood circulation to resolve stasis, thereby relieving pressure and inflammation at the cervical nerve roots. The drug has been evaluated in Phase 3 clinical trials in China (e.g., CTR20191236) to establish its efficacy and safety profile in this patient population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jingzhui Tongluo Capsule.